ME/CFS Science @mecfsscience.org · 27/07/20262) Inebilizumab targets the CD19 a marker on B-cells; the immune cells that produce antibodies. Compared to Rituximab (which targets CD20), inebilizumab targets a broader range of B-cell subsets, including early B cells and plasmablasts. 182
ME/CFS Science @mecfsscience.org · 27/07/20263) The trial also focuses on a very specific subset of ME/CFS patients with elevated antibodies against β2-adrenergic receptors and "a pro-inflammatory immune cell status." 181
ME/CFS Science @mecfsscience.org · 27/07/20264) In addition, the patients must have received immunoadsorption in a previous trial. The must have had an initial positive response to the immunonadsorption followed by a worsening afterwards. Such a pattern suggest that there was a positive effect but it wasn't sustained. 181
